Q-omics provides the consensus-scored SIM1 profile across patient tissues and cancer cell-line models. SIM1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SIM1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SIM1 RNA expression shows 14,186 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where SIM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIM1 survival associations across molecular data types. SIM1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIM1 RNA expression–survival associations across cancer types. High SIM1 expression shows unfavorable associations in UCEC, STAD, ACC, LGG and SKCM, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SIM1 RNA expression.
This table summarizes SIM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SIM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIM1 shows lower tumor expression in KIRC, KIRP, BRCA, READ and PRAD and higher tumor expression in LUAD. The KIRC box plot shows higher SIM1 RNA expression in normal versus tumor tissue (log2 FC = −3.197, t-test p < 0.001).
This table shows molecular features associated with SIM1 in patient tissues and cancer cell lines. In patient samples, SIM1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SIM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
